Can Trulieve Cannabis Corp (TCNNF) Stock Rise to the Top of Healthcare Sector?

Tuesday, August 4, 2020 1:25 PM | InvestorsObserver Analysts

Trulieve Cannabis Corp (TCNNF) is around the middle of the Healthcare sector according to InvestorsObserver.

TCNNF received an overall rating of 83, which means that it scores higher than 83% of stocks. Additionally, Trulieve Cannabis Corp scored a 65 in the Healthcare sector, ranking it higher than 65% of stocks in that sector.

Overall Score - 83
TCNNF has an Overall Score of 83. Find out what this means to you and get the rest of the rankings on TCNNF!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 83 means the stock is more attractive than 83 percent of stocks.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Trulieve Cannabis Corp Stock Today?

Trulieve Cannabis Corp (TCNNF) stock is trading at $18.08 as of 1:06 PM on Tuesday, Aug 4, a rise of $1.26, or 7.49% from the previous closing price of $16.82. The stock has traded between $16.67 and $18.14 so far today. Volume today is 272,182 compared to average volume of 246,148.

To see InvestorsObserver's Sentiment Score for TCNNF click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Sector Update: Afternoon Recovery for Health Care Stocks

Sector Update: Health Care

Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Seelos Therapeutics Inc (SEEL) Stock: What Does the Chart Say?

Related Companies